We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Repare Therapeutics Inc | NASDAQ:RPTX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.02 | -0.57% | 3.51 | 3.50 | 3.84 | 3.66 | 3.445 | 3.56 | 219,390 | 01:00:00 |
From May 2023 to May 2024
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two investor conferences in November. Details for the fireside chats are as follows:
Stifel 2023 Healthcare Conference Date: Tuesday, November 14, 2023 Time: 8:35 a.m. Eastern Time Location: New York, NY
Piper Sandler 35th Annual Healthcare Conference Date: Tuesday, November 28, 2023 Time: 10:30 a.m. Eastern Time Location: New York, NY
A live webcast of the fireside chats can be accessed in the Investor section of the Company’s website at https://ir.reparerx.com/news-and-events/events. A replay of the webcast will be archived on the Company’s website for at least 30 days.
About Repare Therapeutics, Inc.
Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes lunresertib (also known as RP-6306), a PKMYT1 inhibitor currently in Phase 1 clinical development; camonsertib (also known as RP-3500 or RG6526), a potential leading ATR inhibitor currently in Phase 1/2 clinical development and partnered with Roche; RP-3467, a preclinical Polθ inhibitor program; as well as several additional, undisclosed preclinical programs, including RP-1664. For more information, please visit reparerx.com and follow @Reparerx on X (formerly Twitter) and LinkedIn.
SNIPRx® is a registered trademark of Repare Therapeutics Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231106081922/en/
Repare Contact: Steve Forte Executive Vice-President and Chief Financial Officer Repare Therapeutics Inc. investor@reparerx.com
Investors: Matthew DeYoung Argot Partners repare@argotpartners.com
Media: David Rosen Argot Partners david.rosen@argotpartners.com 212-600-1902
1 Year Repare Therapeutics Chart |
1 Month Repare Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
